
A yearlong royalties strife between Genmab and its partner Janssen was finally over in April, when three arbitrators ruled in favor of the latter firm.
Wiping the slate clean with the release of its first quarterly report for 2022, Genmab has announced that it will not seek a review of the award, effectively bringing the entire ordeal to an end. According to CEO Jan van de Winkel, Genmab is now looking to the future.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.